TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Anteris Technologies Announces First Patients Treated in DurAVR® THV Global Pivotal Trial (the “PARADIGM Trial”)

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Anteris Technologies Global Corp.
Anteris Technologies Announces First Patients Treated in DurAVR® THV Global Pivotal Trial (the “PARADIGM Trial”)

Anteris Technologies has enrolled and treated the first patients in its global PARADIGM Trial for the DurAVR® Transcatheter Heart Valve, a study comparing the device's safety and effectiveness against existing transcatheter aortic valve replacements.

Insights
AVR   positive

Company is advancing its medical device through a significant global clinical trial, demonstrating progress in developing innovative healthcare technology